Improving Office Based Treatment of Opioid Use Disorder With Technology
Opioid-use Disorder
About this trial
This is an interventional treatment trial for Opioid-use Disorder focused on measuring opioid abuse, opioid dependence, medication assisted treatment, opioids, buprenorphine, buprenorphine/naloxone, MedicaSafe
Eligibility Criteria
Inclusion Criteria:
- Be between the ages of 18 and 65 years old
- Be able to provide informed consent
- Be English-speaking
- Have consistent phone and/or internet access
- Deemed by physician as medically, psychiatrically, and otherwise appropriate for buprenorphine therapy
- Maintained on a stable B/N dose
Exclusion Criteria:
- Be younger than 18 or older than 65 years of age
- Chronic pain
- Be non-English speaking
- Be unable to complete informed consent
- Be pregnant
Sites / Locations
- Artemis Institute for Clinical Research
- Friends Research InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
BupreCare
Treatment as Usual
Treatment as Usual with MEMS
The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.